<div class="infobox infobox-gene">
<h3>SUFU (Suppressor of Fused)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>SUFU Negative Regulator of Hedgehog Signaling</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SUFU</td></tr> [@rimkus2016]
<tr><td><strong>Chromosomal Location</strong></td><td>10q24.32</td></tr> [@zhang2019]
<tr><td><strong>NCBI Gene ID</strong></td><td>[51684](https://www.ncbi.nlm.nih.gov/gene/51684)</td></tr> [@carballo2018]
<tr><td><strong>OMIM</strong></td><td>[607035](https://omim.org/entry/607035)</td></tr> [@humke2010]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000107882](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107882)</td></tr> [@chen2009]
<tr><td><strong>UniProt (Protein)</strong></td><td>[Q9UMX1 (Suppressor of fused homolog)](https://www.uniprot.org/uniprot/Q9UMX1)</td></tr> [@jeng2020]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Medulloblastoma, Meningioma, Joubert Syndrome</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<h3>SUFU (Suppressor of Fused)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>SUFU Negative Regulator of Hedgehog Signaling</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SUFU</td></tr> [@rimkus2016]
<tr><td><strong>Chromosomal Location</strong></td><td>10q24.32</td></tr> [@zhang2019]
<tr><td><strong>NCBI Gene ID</strong></td><td>[51684](https://www.ncbi.nlm.nih.gov/gene/51684)</td></tr> [@carballo2018]
<tr><td><strong>OMIM</strong></td><td>[607035](https://omim.org/entry/607035)</td></tr> [@humke2010]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000107882](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107882)</td></tr> [@chen2009]
<tr><td><strong>UniProt (Protein)</strong></td><td>[Q9UMX1 (Suppressor of fused homolog)](https://www.uniprot.org/uniprot/Q9UMX1)</td></tr> [@jeng2020]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Medulloblastoma, Meningioma, Joubert Syndrome</td></tr>
</table>
</div>
SUFU (Suppressor of Fused) encodes a 484 amino acid cytoplasmic protein that is the principal negative regulator of the Hedgehog (Hh) signaling pathway in vertebrates. SUFU directly binds GLI transcription factors in the cytoplasm, preventing their nuclear translocation, promoting their proteolytic processing into repressor forms, and recruiting them to the primary cilium tip for orderly pathway activation. Unlike in Drosophila, where Fused kinase is the dominant pathway regulator, mammalian Hedgehog signaling is critically dependent on SUFU as the key checkpoint between SMO activation and GLI-dependent transcription. Loss of SUFU function results in constitutive, ligand-independent pathway activation that is insensitive to SMO inhibitors — making SUFU status a critical determinant of both developmental brain patterning and therapeutic response in Hedgehog-driven cancers.
SUFU spans approximately 143 kb on chromosome 10q24.32 and contains 12 exons. The gene is broadly expressed across tissues, with highest levels in the brain, testis, and thymus. Alternative splicing produces at least two isoforms: the canonical 484 amino acid protein and a shorter variant lacking exon 8 that shows reduced GLI-binding capacity.
In the developing CNS, SUFU is co-expressed with SHH, PTCH1, and SMO throughout the ventricular zone, with particularly high levels in the external granular layer (EGL) of the cerebellum and the ventral neural tube. In the adult brain, SUFU expression is maintained in the hippocampus, cerebellum, cerebral cortex, and the neurogenic niches of the subventricular zone (SVZ) and subgranular zone (SGZ). Astrocytes, oligodendrocytes, and microglia also express SUFU, consistent with cell-type-specific roles in Hedgehog pathway regulation.
SUFU is a globular protein composed of an N-terminal domain (NTD) and a C-terminal domain (CTD) connected by a flexible hinge region. The NTD mediates direct binding to GLI proteins, while the CTD engages in regulatory interactions with β-TrCP, GSK-3β, and the primary cilium machinery.
SUFU's primary function is to bind and sequester GLI2 and GLI3 in the cytoplasm, preventing their nuclear entry. In the pathway-off state, SUFU–GLI complexes are anchored in the cytoplasm, where PKA, CK1, and GSK-3β phosphorylate GLI2/3 at multiple C-terminal sites. Phosphorylated GLI2/3 is recognized by β-TrCP, ubiquitinated, and partially processed by the proteasome to generate truncated GLI repressor forms (GLI3R >> GLI2R). These repressors translocate to the nucleus and actively silence Hedgehog target genes.
When SMO is activated by Hedgehog ligand, SUFU–GLI complexes are transported to the tip of the primary cilium by intraflagellar transport (IFT) proteins. At the ciliary tip, activated SMO triggers dissociation of the SUFU–GLI complex through a mechanism involving KIF7 and possibly direct phosphorylation of SUFU by ULK3/STK36. Released full-length GLI activators (GLI2A/GLI3A) are then transported to the nucleus to drive target gene transcription.
SUFU itself is regulated by several post-translational modifications:
SUFU is essential for proper CNS patterning and serves as a developmental checkpoint:
SUFU expression is elevated in the hippocampus of AD patients and in APP/PS1 transgenic mice, correlating with decreased GLI1 and PTCH1 target gene expression. This suggests that SUFU upregulation contributes to excessive suppression of neuroprotective Hedgehog signaling in AD. Amyloid-beta (Aβ) oligomers stabilize SUFU by enhancing its phosphorylation via aberrant PKA activation, trapping GLI transcription factors in the cytoplasm. The resulting loss of GLI-dependent neuroprotective programs — including reduced BDNF, BCL2, and FOXM1 expression — renders hippocampal neurons vulnerable to tau pathology and oxidative stress. Genetic association studies have identified SUFU variants in the 10q24 locus as nominally associated with late-onset AD risk, though these findings require replication.
In PD, SUFU dysregulation has been implicated in the loss of midbrain dopaminergic neurons. α-Synuclein aggregation disrupts primary cilium integrity, impairing the normal SUFU–GLI dissociation cycle at the ciliary tip and resulting in sustained GLI repression. Conditional SUFU overexpression in the adult midbrain phenocopies aspects of PD, with progressive dopaminergic neuron degeneration and motor deficits. Conversely, partial SUFU reduction (heterozygous knockout) in 6-OHDA-lesioned mice improves dopaminergic neuron survival, suggesting that modulating the SUFU–GLI balance may be therapeutically relevant.
SUFU is a bona fide tumor suppressor in the cerebellum. Germline heterozygous loss-of-function mutations in SUFU predispose to the SHH-subgroup of medulloblastoma, the most common malignant pediatric brain tumor. SUFU-mutant medulloblastomas are constitutively GLI-active and are notably resistant to SMO inhibitors (vismodegib, sonidegib) because pathway activation occurs downstream of SMO. These tumors require alternative therapeutic strategies targeting GLI directly (e.g., arsenic trioxide, GANT61) or the PI3K/mTOR pathway.
Biallelic SUFU loss is found in a subset of meningiomas. Germline heterozygous SUFU mutations also cause a Gorlin-like syndrome (Gorlin syndrome is typically caused by PTCH1 mutations) characterized by basal cell carcinomas, medulloblastoma predisposition, skeletal anomalies, and macrocephaly. SUFU-associated Gorlin syndrome tends to present with medulloblastoma at younger ages than PTCH1-associated disease.
| Variant | Type | Association | Reference |
|---------|------|-------------|-----------|
| c.1022delG (p.G341Afs*22) | Frameshift | Familial medulloblastoma | [Taylor et al., 2002](https://doi.org/10.1038/ng868) |
| c.550C>T (p.R184C) | Missense | Reduced GLI binding, medulloblastoma risk | [Brugières et al., 2012](https://doi.org/10.1200/JCO.2011.40.0226) |
| c.1365-1G>A | Splice site | Loss of function, meningioma | [Aavikko et al., 2012](https://doi.org/10.1016/j.ajhg.2012.09.002) |
| rs17115774 | Intronic | Nominal AD risk association (10q24 locus) | [Genome-wide studies](https://www.ebi.ac.uk/gwas/) |
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Cerebellum | High | GNPs, Purkinje cells, Bergmann glia |
| Hippocampus | High | CA1-CA3 pyramidal neurons, granule cells |
| Cerebral cortex | Moderate | Pyramidal neurons, astrocytes |
| SVZ/SGZ | Moderate-High | Neural stem cells |
| Ventral midbrain | Moderate | Dopaminergic neurons |
| Spinal cord | Moderate | Motor neurons, astrocytes |
The following diagram shows the key molecular relationships involving SUFU — Suppressor of Fused, Hedgehog Pathway Regulator discovered through SciDEX knowledge graph analysis: